Nuformix Reports Results from Preliminary Preclinical Study for NXP002 (inhaled tranilast) in an ex-vivo model of IPF

2nd March 2021

Cambridge, UK – 2 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical development company and drug re-purposing specialist, announces results from a preliminary preclinical study that evaluated NXP002, a proprietary and new physical form of tranilast discovered by Nuformix, in combination with therapies used as standard of care (SOC) in the treatment of idiopathic pulmonary fibrosis (IPF).

 

Download News

Back to all News